title: [French experience of gefitinib in non-small cell bronchial carcinoma].
abstract: BACKGROUND
  Gefitinib (Iressa, ZD 1839; AstraZeneca) is a selective Epidermal Growth Factor receptor tyrosine kinase inhibitor. In two randomized phase II trials (IDEAL 1 and IDEAL 2), it has demonstrated an activity against NSCLC, showing partial response and symptoms improvement rates respectively in about 20% and 40% of patients. Multivariate analyses revealed that being a woman, a non-smoker and having an adenocarcinoma was associated with response rate.
  
  
  METHODS
  We describe a retrospective study of patients receiving Gefitinib as a third line compassionate treatment of NSCLC.
  
  
  RESULTS
  We enrolled 37 patients (29 men, 8 women). Tumors included 25 adenocarcinoma, 4 squamous cell carcinoma, 7 large cell carcinoma, and 1 neuroendocrine carcinoma. Partial response rate was 8.1%, and stable disease rate 27.0%. The 3 responders were all non-smoker women, with an histological type of adenocarcinoma. Symptoms improvement was observed in 59.5% of patients. Main toxicities were diarrhoea and skin reactions. We observed that responding patients had more adverse drugs-related reactions than stable or non-responding patients.
  
  
  CONCLUSIONS
  Gefitinib is a meaningful active therapy in NSCLC with a favorable toxicity profile. We suggest that being a woman, a never-smoker and having an adenocarcinoma may be clinical predictive factors of response to Gefitinib.
authors.affiliation: Service de pneumologie, Hospices Civils de Lyon, Centre hospitalier Lyon-Sud, 165 chemin du Grand Revoyet, 69495 Pierre-Bénite Cedex, France.
authors.forename: N
authors.initials: N
authors.lastname: Girard
authors.forename: L
authors.initials: L
authors.lastname: Gérinière
authors.forename: S
authors.initials: S
authors.lastname: Blandin
authors.forename: E
authors.initials: E
authors.lastname: Perrot
authors.forename: P-J
authors.initials: PJ
authors.lastname: Souquet
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001984:Bronchial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D012737:Sex Factors; D012907:Smoking / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D004815:Epidermal Growth Factor; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib